论文部分内容阅读
目的观察吉西他滨联合顺铂与长春瑞滨联合顺铂治疗晚期乳腺癌的临床疗效。方法将符合病例入选标准的乳腺癌患者160例患者采用随机数字表法分为治疗组和对照组,每组80例。观察组予吉西他滨1 000 mg/m2,静脉滴注30 min,d l,8;顺铂25 mg/m2静脉滴注,d 3～5。对照组予长春瑞滨25 mg/m2,d l,8,溶于生理盐水100 ml中,快速静脉滴注,顺铂25 mg/m2静脉滴注,d 3～5。2组均以治疗21 d为1个周期。观察2组患者的生活质量、临床疗效及不良反应。结果 CR观察组为37.50%,对照组为35.00%,2组相比差异无统计学意义(P﹥0.05)。总有效率观察组为60.00%,对照组为57.50%,2组相比较差异无统计学意义(P﹥0.05)。2组治疗后均出现了不同程度的中性粒细胞减少、贫血、恶心呕吐、脱发、发热、肝功能损害、肾功能损害,但总体而言II-V级发生率两组相比差异无统计学意义(P﹥0.05)。结论吉西他滨联合顺铂与长春瑞滨联合顺铂治疗晚期乳腺癌的临床疗效相当,不良反应相当。
Objective To observe the clinical efficacy of gemcitabine combined with cisplatin and vinorelbine plus cisplatin in the treatment of advanced breast cancer. Methods A total of 160 patients with breast cancer who met the inclusion criteria were divided into treatment group and control group using random number table method, with 80 cases in each group. The observation group was given Gemcitabine 1 000 mg / m2, intravenous infusion 30 min, dl, 8; cisplatin 25 mg / m2 intravenous drip, d3 ~ 5. The control group was given vinorelbine 25 mg / m2, dl, 8, dissolved in 100 ml of normal saline, by rapid intravenous infusion of cisplatin 25 mg / m2 intravenous infusion, d3 ~ 5.2 group were treated for 21 d For 1 cycle. The quality of life, clinical efficacy and adverse reactions in 2 groups were observed. Results The CR observation group was 37.50%, while the control group was 35.00%. There was no significant difference between the two groups (P> 0.05). The total effective rate was 60.00% in the observation group and 57.50% in the control group. There was no significant difference between the two groups (P> 0.05). There were different degrees of neutropenia, anemia, nausea, vomiting, hair loss, fever, liver damage and renal dysfunction in both groups after treatment, but there was no statistical difference in the incidence of grade II-V between the two groups Significance (P> 0.05). Conclusion The clinical efficacy of gemcitabine combined with cisplatin and vinorelbine in combination with cisplatin in the treatment of advanced breast cancer is quite comparable with adverse reactions.